SG11201904535VA - Prevention and treatment of bone and cartilage damage or disease - Google Patents
Prevention and treatment of bone and cartilage damage or diseaseInfo
- Publication number
- SG11201904535VA SG11201904535VA SG11201904535VA SG11201904535VA SG11201904535VA SG 11201904535V A SG11201904535V A SG 11201904535VA SG 11201904535V A SG11201904535V A SG 11201904535VA SG 11201904535V A SG11201904535V A SG 11201904535VA SG 11201904535V A SG11201904535V A SG 11201904535VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bone
- prevention
- treatment
- negative control
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 206010007710 Cartilage injury Diseases 0.000 title abstract 2
- 208000015100 cartilage disease Diseases 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000013642 negative control Substances 0.000 abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- MISZALMBODQYFT-URVXVIKDSA-N 125-69-9 Chemical compound Br.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MISZALMBODQYFT-URVXVIKDSA-N 0.000 abstract 1
- 102100032912 CD44 antigen Human genes 0.000 abstract 1
- 101100227833 Escherichia coli (strain K12) ftnA gene Proteins 0.000 abstract 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 abstract 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 abstract 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451372P | 2017-01-27 | 2017-01-27 | |
| PCT/EP2018/052104 WO2018138322A1 (en) | 2017-01-27 | 2018-01-29 | Prevention and treatment of bone and cartilage damage or disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201904535VA true SG11201904535VA (en) | 2019-08-27 |
Family
ID=61168072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201904535VA SG11201904535VA (en) | 2017-01-27 | 2018-01-29 | Prevention and treatment of bone and cartilage damage or disease |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11517593B2 (da) |
| EP (2) | EP3573630B1 (da) |
| JP (1) | JP7210829B2 (da) |
| KR (1) | KR102580320B1 (da) |
| CN (1) | CN110234329A (da) |
| AU (1) | AU2018211504B2 (da) |
| BR (1) | BR112019013508A2 (da) |
| CA (1) | CA3050099C (da) |
| DK (1) | DK3573630T3 (da) |
| ES (1) | ES2870776T3 (da) |
| IL (1) | IL266772B (da) |
| LT (1) | LT3573630T (da) |
| MX (1) | MX388960B (da) |
| PL (1) | PL3573630T3 (da) |
| PT (1) | PT3573630T (da) |
| SG (1) | SG11201904535VA (da) |
| WO (1) | WO2018138322A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110809583A (zh) | 2017-06-07 | 2020-02-18 | 瑞泽恩制药公司 | 用于内化酶的组合物和方法 |
| KR20200118151A (ko) | 2018-02-07 | 2020-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 치료 단백질 전달을 위한 방법 및 조성물 |
| CA3100021A1 (en) | 2018-05-17 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US12441984B2 (en) | 2019-11-08 | 2025-10-14 | Kansas State University Research Foundation | Isolation, preservation, and expansion of canine umbilical cord mesenchymal stromal cells |
| CN112941021A (zh) * | 2020-03-13 | 2021-06-11 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种骨关节炎关节液来源的间充质干细胞的培养方法 |
| MX2022013939A (es) * | 2020-05-07 | 2023-02-09 | Xintela Ab | Celulas madre para el tratamiento de enfermedades respiratorias. |
| CN113667635A (zh) * | 2020-05-14 | 2021-11-19 | 梦芊科技知识产权有限公司 | 无异源培养基及使用其扩增间充质干细胞的方法 |
| CN112430269B (zh) * | 2021-01-28 | 2021-04-20 | 中赛干细胞基因工程有限公司 | 一种促进脐带血干细胞成骨分化的组合物及其应用 |
| MX2023013709A (es) | 2021-05-20 | 2024-01-16 | Xintela Ab | Celulas madre mesenquimales para usarse en el tratamiento de defectos cutaneos. |
| CA3237493A1 (en) * | 2021-11-15 | 2023-05-19 | Wake Forest University Health Sciences | Tissue regeneration with in vitro activated effector cells |
| JP2025503791A (ja) * | 2022-01-28 | 2025-02-04 | 北京達爾文細胞生物科技有限公司 | 毛包修復タンパク質組成物及びその作製方法とその使用 |
| CN114540298A (zh) * | 2022-03-25 | 2022-05-27 | 北京瑷格干细胞科技有限公司 | 一种干细胞无血清培养基及其制备方法 |
| TW202421655A (zh) * | 2022-10-05 | 2024-06-01 | 全福生物科技股份有限公司 | 用於骨頭/軟骨再生之包含pedf衍生短肽及間質幹細胞之組合物 |
| CN115651076B (zh) * | 2022-12-09 | 2023-09-29 | 北京大学口腔医学院 | 人骨髓间充质干细胞来源凋亡囊泡的表面标志物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1276486E (pt) * | 2000-04-25 | 2011-02-07 | Osiris Therapeutics Inc | Reparação de articulação utilizando células estaminais do mesênquima |
| ATE384079T1 (de) | 2002-06-14 | 2008-02-15 | Cartela Ab | Marker für stammzellen und dessen verwendung |
| SE0301087D0 (sv) * | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
| WO2007099337A1 (en) * | 2006-03-01 | 2007-09-07 | Cartela R&D Ab | Expansion and differentiation of mesenchymal stem cells |
| WO2008072000A2 (en) | 2006-12-15 | 2008-06-19 | Xintela Ab (Se) | Use of integrin alpha 10 binding antibody to modulate extracellular matrix ( cartilage) turnover |
| US20090029463A1 (en) * | 2007-07-25 | 2009-01-29 | Bioe, Inc. | Differentiation of Multi-Lineage Progenitor Cells to Chondrocytes |
-
2018
- 2018-01-29 DK DK18703531.6T patent/DK3573630T3/da active
- 2018-01-29 ES ES18703531T patent/ES2870776T3/es active Active
- 2018-01-29 BR BR112019013508-1A patent/BR112019013508A2/pt not_active Application Discontinuation
- 2018-01-29 LT LTEP18703531.6T patent/LT3573630T/lt unknown
- 2018-01-29 CN CN201880008965.1A patent/CN110234329A/zh active Pending
- 2018-01-29 PL PL18703531T patent/PL3573630T3/pl unknown
- 2018-01-29 PT PT187035316T patent/PT3573630T/pt unknown
- 2018-01-29 EP EP18703531.6A patent/EP3573630B1/en active Active
- 2018-01-29 KR KR1020197022614A patent/KR102580320B1/ko active Active
- 2018-01-29 CA CA3050099A patent/CA3050099C/en active Active
- 2018-01-29 SG SG11201904535VA patent/SG11201904535VA/en unknown
- 2018-01-29 AU AU2018211504A patent/AU2018211504B2/en active Active
- 2018-01-29 WO PCT/EP2018/052104 patent/WO2018138322A1/en not_active Ceased
- 2018-01-29 EP EP21162806.0A patent/EP3919064A1/en not_active Withdrawn
- 2018-01-29 JP JP2019535889A patent/JP7210829B2/ja active Active
- 2018-01-29 MX MX2019008872A patent/MX388960B/es unknown
-
2019
- 2019-05-21 IL IL266772A patent/IL266772B/en unknown
- 2019-07-23 US US16/519,179 patent/US11517593B2/en active Active
-
2022
- 2022-11-01 US US17/978,300 patent/US20230128397A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230128397A1 (en) | 2023-04-27 |
| DK3573630T3 (da) | 2021-06-07 |
| PT3573630T (pt) | 2021-05-06 |
| MX2019008872A (es) | 2019-09-18 |
| WO2018138322A1 (en) | 2018-08-02 |
| AU2018211504A1 (en) | 2019-07-04 |
| CA3050099A1 (en) | 2018-08-02 |
| KR20190107686A (ko) | 2019-09-20 |
| CA3050099C (en) | 2024-04-16 |
| ES2870776T3 (es) | 2021-10-27 |
| CN110234329A (zh) | 2019-09-13 |
| BR112019013508A2 (pt) | 2020-01-07 |
| IL266772B (en) | 2022-04-01 |
| JP7210829B2 (ja) | 2023-01-24 |
| EP3573630A1 (en) | 2019-12-04 |
| EP3919064A1 (en) | 2021-12-08 |
| IL266772A (en) | 2019-07-31 |
| AU2018211504B2 (en) | 2022-08-18 |
| LT3573630T (lt) | 2021-05-25 |
| JP2020505916A (ja) | 2020-02-27 |
| US11517593B2 (en) | 2022-12-06 |
| MX388960B (es) | 2025-03-20 |
| PL3573630T3 (pl) | 2021-09-13 |
| EP3573630B1 (en) | 2021-03-17 |
| KR102580320B1 (ko) | 2023-09-19 |
| US20200038449A1 (en) | 2020-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201907857RA (en) | Edible and biodegradable utensils | |
| SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909041SA (en) | Anti-pd-l1 antibody and use thereof | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201900058YA (en) | Method of generating mesenchymal stem cells and uses thereof | |
| SG11201901594RA (en) | Cell suspension for use in the treatment of lower extremity peripheral artery disease | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
| SG11201908042TA (en) | Smartcard | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201811763SA (en) | B-cell-mimetic cells |